IMNM supply chain intelligence for Immunome, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Immunome, Inc. (IMNM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AYALA-PHARMACEUTICALS-INC | AYALA-PHARMACEUTICALS-INC | 80% | In connection with the closing of the Ayala Purchase Agreement in March 2024, the Company assumed a license agreement, the BMS License Agreement, with Bristol-Myers Squibb Company, or BMS, pursuant t… |
| BMY | Bristol-Myers Squibb Company | 72% | riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and development expenses Intangible assets acquired in an asset acquisition or license… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: riod. No further collaboration revenu… |
| BMYMP | Bristol-Myers Squibb Co | 72% | riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and development expenses Intangible assets acquired in an asset acquisition or license… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and… |
| JNJ | Johnson & Johnson | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| LLY | Eli Lilly and Company | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impo… |
| MYGN | Myriad Genetics, Inc. | 72% | -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addit… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulator… |
| NVSEF | Novartis AG | 72% | third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement actions; private litigation (including cla… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: ernment regulation that may arise from future legislation or administrative or executive action, either in the Unite… |
| ORANY | ORANY | 72% | ernment regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, imp… |
| SNYNF | Sanofi | 72% | -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addit… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on … |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial competition, which may result in others discov… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ABBV | AbbVie Inc. | 85% | Reciprocal relationship from ABBV graph: Reciprocal relationship from IMNM graph: generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have gene… |
| ABBVIE-GLOBAL-ENTERPRISES-LTD | ABBVIE-GLOBAL-ENTERPRISES-LTD | 85% | generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have generated our revenue through a Collaboration and Option Agreement, or the Collaborati… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s co… |
| BMY | Bristol-Myers Squibb Company | 72% | er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s common stock at an aggregate fair value of $ million on the acquisition date. The f… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s … |
| BMYMP | Bristol-Myers Squibb Co | 72% | er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s common stock at an aggregate fair value of $ million on the acquisition date. The f… |
| JNJ | Johnson & Johnson | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from JNJ grap… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY grap… |
| LLY | Eli Lilly and Company | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| MYGN | Myriad Genetics, Inc. | 72% | ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, discl… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from MYGN g… |
| NVSEF | Novartis AG | 72% | third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement actions; private litigation (including cla… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: third parties with whom we work) … |
| ORANY | ORANY | 72% | ernment regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: ernment regulation that may arise… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or acc… |
| SNYNF | Sanofi | 72% | ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, discl… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on … |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial competition, which may result in others discov… |
| AMGN | Amgen Inc. | 62% | Reciprocal relationship from AMGN graph: Reciprocal relationship from IMNM graph: security incident or other interruption that has, and could in the future, result in unauthorized, unlawful, or accid… |
| AYALA-PHARMACEUTICALS-INC | AYALA-PHARMACEUTICALS-INC | 62% | nder Section 401(k) of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a por… |
| BAYER-AG | BAYER-AG | 62% | in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; • participants who enroll in clinical trials may later drop out due … |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | manner and may discover deficiencies in existing systems and controls. Our employees, principal investigators, vendors and commercial partners may engage in misconduct or other improper activities, i… |
| IN-AMGEN-INC | IN-AMGEN-INC | 62% | security incident or other interruption that has, and could in the future, result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclo… |
| USA-LLC | USA-LLC | 62% | nnel-related costs from an increase in headcount, including a $1.0 million increase in share-based compensation. Interest income Interest income increased by $2.5 million from $3.0 million for the th… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IMNM-DEBT | Debt stack $500,000 | 90% | Market cache reports total debt of $500,000. |
| IMNM-DEBT-10242 | Warrants outstanding: 10 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| IMNM-DEBT-10243 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IMNM-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 200 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 |